Skip to content
Companies

BioLattice Ophthalmics

Synthetic cornea implant to replace donor tissue

Raised to date

$575K

of $2.5M offered across 1 Form D filing

Still open
$1.9M
Investors
2
Last filed
Mar 30, 2026

About

BioLattice Ophthalmics is a Philadelphia biotech developing engineered corneal tissue to replace human donor corneas. Its lead product, CorneaClear, is a synthetic, biocompatible, room-temperature-stable corneal implant intended to be implanted using the same procedure surgeons already use for donor tissue. The company targets corneal blindness, which it describes as affecting roughly 2 million new patients a year with only about 1 in 70 patients who need cornea tissue receiving it. It was co-founded by Amelia Zellander (Chief Scientific Officer) and Linda Alunkal (Chief Executive Officer), has an NSF SBIR Phase I grant, and went through SOSV's IndieBio program.

A shelf-stable synthetic cornea removes both the donor-tissue supply constraint and the cold chain, while mirroring the existing donor-implant surgical procedure so surgeons need minimal retraining - and its eye-compatible materials are intended to lower rejection risk and reduce dependence on anti-rejection medication compared with donor grafts and existing keratoprostheses.

Funding

  • EquityFiled Mar 30, 2026Form D
    $575K/ $2.5M

Product

CorneaClear

Ophthalmic implant / medical device

An engineered synthetic cornea: a biocompatible, room-temperature-stable implant designed as an alternative to donor corneal tissue for corneal replacement surgery.

  • Synthetic, eye-compatible material rather than human donor tissue
  • Room-temperature stable and shelf-storable, eliminating cold chain logistics
  • Implantation mirrors the donor tissue procedure, requiring minimal surgeon training

Built for

Corneal surgeons, eye hospitals and transplant programs treating patients with corneal blindness

People on file